CStone PharmaceuticalsHKEX: 2616

Interim report 2026

· Issued by CStone Pharmaceuticals via HKEXnews

Filed with HKEX · Stock code 2616 · · 98 pages · English

Summary by 6ix AI

The report indicates significant revenue growth driven by increased sales of pharmaceutical products, particularly following the inclusion of pralsetinib in a national reimbursement list. The report also outlines ongoing research and development efforts and strategic partnerships aimed at enhancing its market presence.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

CStone Pharmaceuticals on 6ix

Earlier from CStone Pharmaceuticals

Later from CStone Pharmaceuticals

All CStone Pharmaceuticals news releases